Latest News for: cytotoxic t cells

Edit

Chinese team develops breakthrough vaccine molecule

China Daily 27 Mar 2025
The development of an innovative vaccine technology for stimulating responses from cytotoxic CD8+ T cells might aid efforts to design better vaccines for cancer and other diseases, said John T.
Edit

Heidelberg Pharma to Present Data from its ADC Technology Platforms at AACR Annual Meeting 2025

Pharmiweb 26 Mar 2025
Selected antibodies are loaded with cytotoxic compounds, the so-called payloads, that are transported into diseased cells. Inside the cells, the toxins then unleash their effect and kill the diseased cells.
Edit

Colorectal Cancer Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, ...

GetNews 26 Mar 2025
It is designed to target and deliver chemotherapy inside cancer cells and reduce systemic exposure to the cytotoxic payload (or chemotherapy) compared to the way chemotherapy is commonly delivered.
Edit

Breast Cancer Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, ...

GetNews 25 Mar 2025
... the lysosome to release small Molecular toxins eventually induce tumor cell apoptosis, combining the high targeting of antibodies and the powerful killing power of cytotoxic drugs on target cells.
Edit

Non-Hodgkin’s Lymphoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, ...

GetNews 25 Mar 2025
... B-cell Non-hodgkin's Lymphoma ... Mosunetuzumab is an investigational, humanized, T-cell bispecific antibody designed to engage T cells and redirect their cytotoxic activity against malignant B cells.
Edit

Bladder Cancer Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, ...

GetNews 25 Mar 2025
... cell cycle ... The drug kills tumor cells by engaging T cell and accessory cell mediated cytotoxicity and has the potential to induce long-term vaccinal effects which has been verified in animal models.
Edit

Heidelberg Pharma announces financial figures and reports on successful business performance in 2024

Pharmiweb 21 Mar 2025
HDP-102 is an ATAC targeting CD37 that is expressed on B-cell lymphoma cells ... Selected antibodies are loaded with cytotoxic compounds, the so-called payloads, that are transported into diseased cells.
Edit

Metastatic Breast Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, ...

GetNews 19 Mar 2025
ADCs are a therapeutic modality consisting of an antibody molecule linked to a highly cytotoxic agent, and is typically designed to specifically deliver chemotherapies to tumor cells.
Edit

Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy

ACCESSWIRE 18 Mar 2025
APVO603 is designed to activate the costimulatory 4-1BB and OX40 pathways in the tumor microenvironment, leading to enhanced T cell expansion, survival, and cytotoxic function while avoiding systemic toxicity.
Edit

NK Cell Therapy Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, IND, NDA Approval, ...

GetNews 17 Mar 2025
NK cells, known for their innate cytotoxicity against tumor cells, are being increasingly explored in clinical applications, with promising trial results supporting their potential in cancer treatment.
Edit

New cancer-killing compounds discovered in Việt Nam’s seas

Vietnam News 15 Mar 2025
... cell-killing properties ... Several of these exhibited significant cytotoxicity, particularly against prostate and lung cancer cell lines, offering promising prospects for cancer treatment research.
Edit

Cell Based Assays Market is Projected to Surpass USD 40.4 billion by 2034 with a 6.4% CAGR,| According to TMR

Pharmiweb 14 Mar 2025
Cell-based screening is used in drug development and biomedical research to accurately measure off-target interactions, biochemical processes, biological activity, and cytotoxicity.
Edit

Releasing the Brakes: The Role of Immune Checkpoint Inhibitors in Cancer Therapy

The Scientist 13 Mar 2025
There are several classes of T cells including CD4+ helper T cells, CD8+ cytotoxic T cells, regulatory T cells, and memory T cells.
Edit

GenFleet Therapeutics Receives Clinical Trial Approval from China’s NMPA for GFS202A, a Bispecific Antibody Targeting ...

GetNews 13 Mar 2025
... promoting growth, migration, and proliferation of cancer cells. Additionally, it inhibits DC (dendritic cell)-mediated T-cell stimulation and the activation and infiltration of cytotoxic T cells.
Edit

Heidelberg Pharma Amends Royalty Financing with HealthCare Royalty

Pharmiweb 13 Mar 2025
Selected antibodies are loaded with cytotoxic compounds, the so-called payloads, that are transported into diseased cells. Inside the cells, the toxins then unleash their effect and kill the diseased cells.
×